Valuation
- Market cap
- 10,729,000
- Revenue TTM
- $0
- Net income TTM
- $-26,260,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 55,885
- Avg volume
- 3,269,558
- Day's range
- $0.62 – $0.67
- Shares out
- 16,890,000
- Stochastic %K
- 7%
- Beta
- -1.73
- Analysts
- Sell
- Price target
- $7.00
Company profile
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule...
Show more
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement
with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 415 798 8589
- Website
- https://www.tempesttx.com
- Address
- 2000 Sierra Point Parkway, Suite 400, Brisbane, United States
Latest news
No headlines yet.
